Abstract S5-05: Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study

作者
Hans P. M. W. Wildiers,S-B. Kim,Antonio González-Martı́n,Patricia Mucci LoRusso,J-M Ferrero,Ron Yu,Melanie C. Smitt,Ian E. Krop
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:76 (4_Supplement): S5-05 被引量:20
标识
DOI:10.1158/1538-7445.sabcs15-s5-05
摘要

Abstract Introduction The phase 3, randomized, open-label, TH3RESA study (BO25734/TDM4997g; NCT01419197) compared trastuzumab emtansine (T-DM1) with treatment of physician's choice (TPC) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), previously treated with a taxane (any setting), and both trastuzumab and lapatinib (advanced setting). Progression-free survival (PFS) and overall survival (OS) were co-primary endpoints. Results of the primary PFS analysis and the first interim OS analysis showed significantly improved PFS with T-DM1 compared with TPC and a trend for improved OS, although the stopping boundary was not reached (Krop IE, et al. Lancet Oncol 2014). The incidence of grade ≥3 adverse events (AEs) was lower with T-DM1 vs TPC (32% vs 43%). Here we report the results from the second interim analysis of OS from TH3RESA, which will serve as the final OS results. Methods Eligible patients were randomized 2:1 to receive T-DM1 (3.6 mg/kg IV every 3 weeks) or TPC. The pre-specified OS efficacy stopping boundary was an observed hazard ratio (HR) <0.75 or p<0.012. Crossover from TPC to T-DM1 following progressive disease was allowed from Sept 2012 onward. Results From Sept 14, 2011 to Nov 19, 2012, 602 patients were randomized to T-DM1 (n=404) or TPC (n=198). TPC comprised HER2-directed regimens (83%) and single-agent chemotherapy (17%). At the data cutoff for this analysis (Feb 13, 2015), 93 patients (47%) had crossed over from TPC to T-DM1. At a median follow-up time of 30.5 months, OS was significantly longer with T-DM1 vs TPC (median OS 22.7 vs 15.8 months; HR=0.68 [95% CI, 0.54–0.85; p=0.0007]) and these results crossed the OS efficacy stopping boundary. A sensitivity analysis, in which patients were censored when they switched from TPC to T-DM1, also showed an OS benefit with T-DM1 vs TPC (median 22.7 vs 15.6 months; HR=0.58 [95% CI: 0.43–0.77; p=0.0002]). The OS benefit was consistently observed across subgroups defined by age, visceral involvement, hormone receptor status, number of prior regimens, and TPC type. The T-DM1 group had nearly twice the mean exposure to the planned study treatment as the TPC group (7.93 vs 4.08 months). In treated patients, the incidence of grade ≥3 AEs was 40.0% and 47.3% in the T-DM1 and TPC arms, respectively. Grade ≥3 AEs occurring in ≥3% of either treatment arm were neutropenia (T-DM1, 2.5%; TPC, 15.8%), febrile neutropenia (T-DM1, 0.2%; TPC, 3.8%), thrombocytopenia (T-DM1, 6.0%; TPC, 2.7%), anemia (T-DM1, 3.5%; TPC, 3.3%), dyspnea (T-DM1, 2.5%; TPC, 3.8%), diarrhea (T-DM1, 0.7%; TPC, 4.3%), and asthenia (T-DM1, 1.0%; TPC, 3.3%). Conclusions In this population of patients with advanced breast cancer who previously received a taxane, trastuzumab, and lapatinib, treatment with T-DM1 resulted in a statistically significant and clinically meaningful improvement in OS compared with TPC. A lower incidence of grade ≥3 AEs was observed with T-DM1 and its safety profile was consistent with previous studies. These data further solidify the role of T-DM1 in the treatment of previously treated HER2-positive advanced breast cancer. Citation Format: Wildiers H, Kim S-B, Gonzalez-Martin A, LoRusso PM, Ferrero J-M, Yu R, Smitt M, Krop I. Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr S5-05.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个的应助被东风知我欲采纳,获得30
2秒前
3秒前
youknowdcf发布了新的文献求助10
3秒前
Akim的应助被yiyi1采纳,获得20
3秒前
3秒前
4秒前
zhouyang发布了新的文献求助10
4秒前
5秒前
7秒前
田様的应助被xxxg郭采纳,获得10
8秒前
汉堡包的应助被cc采纳,获得10
8秒前
虾米君完成签到,获得积分10
8秒前
9秒前
溜溜梅棒棒棒完成签到,获得积分10
9秒前
FashionBoy的应助被motal采纳,获得10
9秒前
春风失意发布了新的文献求助10
10秒前
耶稣与梦完成签到,获得积分10
11秒前
Pao完成签到,获得积分10
11秒前
ZXheng完成签到,获得积分10
12秒前
12秒前
14秒前
DW的应助被汤易文采纳,获得10
14秒前
14秒前
mugi3055完成签到 ,获得积分10
14秒前
zhangpeiguo完成签到,获得积分10
16秒前
Ariel发布了新的文献求助10
16秒前
16秒前
17秒前
沉默笑翠完成签到,获得积分10
18秒前
爆米花的应助被youknowdcf采纳,获得10
19秒前
19秒前
西陆发布了新的文献求助10
19秒前
JeanetteJin发布了新的文献求助10
20秒前
20秒前
哒哒完成签到,获得积分10
20秒前
20秒前
cc完成签到,获得积分10
21秒前
蔡翌文完成签到 ,获得积分10
21秒前
NASA_FAST发布了新的文献求助30
21秒前
zhouyang完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177667
求助须知:如何正确求助?哪些是违规求助? 9568537
关于积分的说明 21799700
捐赠科研通 7772307
什么是DOI,文献DOI怎么找? 3432429
关于科研通互助平台的介绍 2556651
邀请新用户注册赠送积分活动 2478011